Amgen Highlights Data To Be Presented At 2015 American College Of Rheumatology And Association For Rheumatology Health Professionals Annual Meeting

THOUSAND OAKS, Calif., Nov. 4, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present key results from several studies related to Enbrel® (etanercept) and ABP 501, an adalimumab biosimilar candidate, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Meeting in San Francisco, Nov. 7-11, 2015. These data reinforce Amgen's continued commitment to delivering high-quality medicines that may help to improve the lives of people with serious rheumatologic diseases.



Amgen - Investors - RSS Content